Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immuunsuse tagajärgi on tõestatud üks nädal pärast esmast vaktsinatsioonikursust rinotrahheiidi, kalitsiviiruse, chlamydophila felis ja panleukopeenia komponentide jaoks. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinantse türgi herpesvirus, tüvi vhvt013-69, live - immunoloogilised ravimid jaoks linnud, kodukana, immunoloogilised ravimid - embryonated eggs; chicken - aktiivse immuniseerimise kanade:selleks, et ära hoida suremust ja vähendada kliinilisi tunnuseid ja kahjustused nakkav haiguse bursal. vähendada suremust, kliinilisi tunnuseid ja kahjustuste marek tõbi.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamitromütsiin - antibakteriaalsed ained süsteemseks kasutamiseks - cattle; pigs; sheep - cattletreatment ja metaphylaxis veiste hingamisteede haigusi (brd) on seotud mannheimia haemolytica, pasteurella multocida ja histophilus somni. haiguse olemasolu karjas, tuleks kehtestada enne metaphylactic kasutada. pigstreatment sigade hingamisteede haigus (erm) seotud actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis ja bordetella bronchiseptica. sheeptreatment nakkav pododermatitis (suu mäda) seotud virulent dichelobacter nodosus ja fusobacterium necrophorum vajavad süsteemset ravi.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - sigade tsirkoviiruse tüüp 2 orf2 valk - sigalaste immunoloogilised omadused - sead - aktiivse immuniseerimise sigade nr pcv2 emalt saadud antikehad alates vanusest 2 nädalat vastu sead circovirus tüüp 2 (pcv2),.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - chondrogenic põhjustatud hobuste allogeense perifeerse vere-tuletatud mesenchymal tüvirakkude - muud lihas-skeleti süsteemi häirete ravimid - hobused - vähendada kerge kuni mõõduka korduva lonkamine seotud mitte-septiline liigesepõletik hobused.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - ektoparasiitsiidid süsteemseks kasutamiseks - koerad - ravi kirbu (ctenocephalides felis ja c.. canis) infestatsioonid. seda toodet saab kasutada kirbuallergia dermatiidi (fad) ravistrateegia osana.. ravi rist (dermacentor reticulatus, ixodes ricinus, rhipicephalus sanguineus) infestatsioonid. ravi demodicosis (põhjustatud demodex canis). ravi sarcoptic mange (põhjustatud sarcoptes scabiei var. canis).

Den Europæiske Union - estisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - sead parvovirus, liin 27a, viiruse valk 2 - sigalaste immunoloogilised omadused - sead - aktiivse immuniseerimise kohta nooremiste ja emiste puhul alates vanusest 5 kuud kaitsta järglaste vastu transplatsentaarse nakatumise põhjustatud sigade parvovirus.